Three biotechs advanced Wall Street momentum with large, upsized IPOs as equity appetite for early commercial potential persists. Seaport Therapeutics raised $254.9 million gross on a Nasdaq debut after Puretech moved to a sole listing on the London Stock Exchange; Hemab priced an upsized offering for $301.5 million gross; and additional IPO pricing coverage highlighted similar demand signals for the broader biotech pipeline. The deals underscore that investors are still underwriting specialty development stories—neuroscience and clotting disorders in particular—despite a selective risk environment. The proceeds also add near-term runway for trial execution as companies transition from private-stage development to public-market milestones. For biotech finance watchers, the pattern suggests that scale and pricing power matter: the companies’ overshoots versus initial expectations point to strong demand at the top of the range.